Cytosorbents Crp (CTSO)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $15.35M
Last updated: Nov 17, 2026 at 11:04 AM ET
Cytosorbents Crp (CTSO) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Cytosorbents Crp reported EPS of -$0.58, above the -$0.90 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CTSO's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
CTSO Earnings Call
The latest CTSO earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, CTSO beat 16, missed 20 and matched 4. The widest gap in the table came in the quarter ended Dec 31, 2024, when EPS landed 162.66% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.58 | -$0.90 | -$1.00 - -$0.80 | +35.56% | Beat | N/A | 2 | 0 up, 2 down | Nov 12, 2026 | N/A |
| Jun 30, 2026 | -$0.07 | -$0.05 | -$0.05 - -$0.04 | -40.00% | Miss | N/A | 3 | 1 up, 0 down | Aug 6, 2026 | $9.63M |
| Mar 31, 2026 | -$0.08 | -$0.05 | -$0.06 - -$0.05 | -60.00% | Miss | N/A | 2 | 0 up, 0 down | May 13, 2026 | $8.86M |
| Dec 31, 2025 | -$0.09 | -$0.04 | -$0.06 - -$0.04 | -104.08% | Miss | N/A | 3 | 1 up, 1 down | Mar 25, 2026 | $9.23M |
| Sep 30, 2025 | -$0.05 | -$0.05 | -$0.06 - -$0.03 | 0.00% | In line | N/A | 3 | 0 up, 1 down | Nov 13, 2025 | $9.48M |
| Jun 30, 2025 | -$0.05 | -$0.07 | N/A | +28.57% | Beat | N/A | N/A | 0 up, 0 down | Aug 7, 2025 | $9.62M |
| Mar 31, 2025 | -$0.02 | -$0.07 | N/A | +71.43% | Beat | N/A | N/A | 0 up, 0 down | May 14, 2025 | $8.73M |
| Dec 31, 2024 | -$0.14 | -$0.05 | N/A | -162.66% | Miss | N/A | N/A | 0 up, 0 down | Mar 31, 2025 | $9.15M |
| Sep 30, 2024 | -$0.08 | -$0.06 | -$0.08 - -$0.05 | -33.33% | Miss | N/A | 3 | 0 up, 0 down | Nov 7, 2024 | $8.61M |
| Jun 30, 2024 | -$0.08 | -$0.10 | -$0.11 - -$0.09 | +20.00% | Beat | N/A | 4 | 0 up, 0 down | Aug 13, 2024 | $8.84M |
| Mar 31, 2024 | -$0.12 | -$0.12 | -$0.15 - -$0.10 | 0.00% | In line | N/A | 3 | 0 up, 0 down | May 9, 2024 | $8.99M |
| Dec 31, 2023 | -$0.13 | -$0.14 | -$0.22 - -$0.08 | +7.14% | Beat | N/A | 4 | 0 up, 0 down | Mar 14, 2024 | $3.40M |
| Sep 30, 2023 | -$0.21 | -$0.12 | -$0.14 - -$0.10 | -75.00% | Miss | N/A | 6 | 0 up, 0 down | Nov 9, 2023 | $8.81M |
| Jun 30, 2023 | -$0.14 | -$0.14 | -$0.16 - -$0.04 | 0.00% | In line | N/A | 4 | 0 up, 0 down | Aug 1, 2023 | $9.42M |
| Mar 31, 2023 | -$0.17 | -$0.13 | -$0.16 - -$0.08 | -30.77% | Miss | N/A | 3 | 0 up, 0 down | May 2, 2023 | $9.45M |
| Dec 31, 2022 | -$0.01 | -$0.01 | N/A | -33.33% | Miss | N/A | 5 | 0 up, 0 down | Mar 9, 2023 | $9.39M |
| Sep 30, 2022 | -$0.28 | -$0.16 | -$0.19 - -$0.13 | -75.00% | Miss | N/A | 4 | 0 up, 0 down | Nov 3, 2022 | $8.11M |
| Jun 30, 2022 | -$0.25 | -$0.12 | -$0.18 - -$0.07 | -108.33% | Miss | N/A | 4 | 0 up, 0 down | Aug 2, 2022 | $8.50M |
| Mar 31, 2022 | -$0.21 | -$0.14 | -$0.17 - -$0.07 | -50.00% | Miss | N/A | 4 | 0 up, 0 down | May 3, 2022 | $8.69M |
| Dec 31, 2021 | -$0.21 | -$0.13 | -$0.18 - -$0.07 | -61.54% | Miss | N/A | 5 | 0 up, 0 down | Mar 8, 2022 | $10.78M |
| Sep 30, 2021 | -$0.15 | -$0.12 | -$0.14 - -$0.06 | -25.00% | Miss | N/A | 5 | 0 up, 0 down | Nov 4, 2021 | $9.76M |
| Jun 30, 2021 | -$0.11 | -$0.05 | -$0.06 - $0.03 | -120.00% | Miss | N/A | 7 | N/A | Aug 3, 2021 | $12.02M |
| Mar 31, 2021 | -$0.10 | -$0.05 | -$0.09 - $0.06 | -100.00% | Miss | N/A | 6 | N/A | May 4, 2021 | $10.60M |
| Dec 31, 2020 | -$0.01 | -$0.04 | -$0.07 - $0.01 | +75.00% | Beat | N/A | 8 | N/A | Mar 9, 2021 | $11.96M |
| Sep 30, 2020 | -$0.02 | -$0.09 | -$0.14 - -$0.05 | +77.78% | Beat | N/A | 8 | N/A | Nov 4, 2020 | $10.55M |
| Jun 30, 2020 | -$0.08 | -$0.09 | -$0.11 - -$0.05 | +11.11% | Beat | N/A | 6 | N/A | Aug 4, 2020 | $9.79M |
| Mar 31, 2020 | -$0.10 | -$0.15 | -$0.21 - -$0.09 | +33.33% | Beat | N/A | 4 | N/A | May 5, 2020 | $8.71M |
| Dec 31, 2019 | -$0.12 | -$0.16 | -$0.23 - -$0.10 | +25.00% | Beat | N/A | 5 | N/A | Mar 5, 2020 | $7.43M |
| Sep 30, 2019 | -$0.21 | -$0.14 | -$0.18 - -$0.11 | -50.00% | Miss | N/A | 5 | N/A | Nov 5, 2019 | $6.10M |
| Jun 30, 2019 | -$0.11 | -$0.14 | -$0.17 - -$0.10 | +21.43% | Beat | N/A | 5 | N/A | Aug 6, 2019 | $6.23M |
| Mar 31, 2019 | -$0.15 | -$0.18 | -$0.22 - -$0.15 | +16.67% | Beat | N/A | 3 | N/A | May 7, 2019 | $5.19M |
| Dec 31, 2018 | -$0.17 | -$0.13 | -$0.15 - -$0.12 | -30.77% | Miss | N/A | 5 | N/A | Mar 7, 2019 | $6.08M |
| Sep 30, 2018 | -$0.10 | -$0.14 | -$0.16 - -$0.12 | +28.57% | Beat | N/A | 4 | N/A | Nov 6, 2018 | $5.74M |
| Jun 30, 2018 | -$0.19 | -$0.13 | -$0.15 - -$0.05 | -46.15% | Miss | N/A | 4 | N/A | Aug 2, 2018 | $5.76M |
| Mar 31, 2018 | -$0.10 | -$0.13 | -$0.16 - -$0.03 | +23.08% | Beat | N/A | 4 | N/A | May 8, 2018 | $4.92M |
| Dec 31, 2017 | -$0.11 | -$0.09 | -$0.14 - -$0.06 | -22.22% | Miss | N/A | 4 | N/A | Mar 8, 2018 | $4.65M |
| Sep 30, 2017 | -$0.07 | -$0.07 | -$0.11 - -$0.05 | 0.00% | In line | N/A | 5 | N/A | Nov 9, 2017 | $3.82M |
| Jun 30, 2017 | -$0.04 | -$0.06 | -$0.07 - -$0.05 | +33.33% | Beat | N/A | 5 | N/A | Aug 7, 2017 | $3.57M |
| Mar 31, 2017 | -$0.05 | -$0.10 | N/A | +50.00% | Beat | N/A | N/A | N/A | May 8, 2017 | $3.11M |
| Dec 31, 2016 | -$0.17 | -$0.09 | N/A | -88.89% | Miss | N/A | N/A | N/A | Mar 3, 2017 | $3.08M |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.21, after -$0.42 the year before. It was -$0.48 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.21 | N/A |
| Dec 31, 2024 | -$0.42 | N/A |
| Dec 31, 2023 | -$0.65 | N/A |
| Dec 31, 2022 | -$0.75 | N/A |
| Dec 31, 2021 | -$0.57 | N/A |
| Dec 31, 2020 | -$0.21 | N/A |
| Dec 31, 2019 | -$0.59 | N/A |
| Dec 31, 2018 | -$0.56 | N/A |
| Dec 31, 2017 | -$0.27 | N/A |
| Dec 31, 2016 | -$0.48 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,000 words across 5 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,955 | 5 | |
| 2026Q2 | Jun 30, 2026 | 8,166 | 6 | |
| 2026Q1 | Mar 31, 2026 | 5,719 | 7 | |
| 2025Q4 | Dec 31, 2025 | 3,789 | 7 | |
| 2025Q3 | Sep 30, 2025 | 2,867 | 5 | |
| 2025Q2 | Jun 30, 2025 | 3,505 | 6 | |
| 2025Q1 | Mar 31, 2025 | 5,314 | 8 | |
| 2024Q3 | Sep 30, 2024 | 5,123 | 6 |
2026Q3 Earnings Call
Opening remarks
Peter Mariani CFO Thank you, John, and good afternoon, everyone. Joining me on today's call is Dr. Phillip Chan, our Chief Executive Officer. As we get started this evening, I want to remind everyone that our press release has been filed and is available with the SEC, but given the several delays that many of us have experienced today, apparently there's a delay with the wire service, so hopefully we'll see that cross the wire here very soon. On today's call, we will review our third quarter 2026 operating and financial results, including the key milestone highlighted in today's earnings release, the achievement of our first value driver, operating cash flow breakeven. We will then provide an update on our remaining value drivers, including our regulatory progress with DrugSorb-ATR, followed by a question-and-answer session. Before we begin, I'd like to remind everyone that statements made during this call that are not historical facts are forward-looking statements, and the company claims protection under the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. These statements include, among others, statements about our plans, objectives, future targets and outlook, our ability to sustain operating cash flow breakeven, the outcome of our regulatory submissions, our ability to maintain compliance with NASDAQ continued listing requirements, and our ability to finance the company, including the extension, refinancing, or repayment of our existing debt. Actual results may differ materially from those expressed or implied in these statements. For the discussion of risks and uncertainties that could cause such differences, please refer to the risk factors in our annual report on Form 10-K filed with the SEC on March 30, 2026, as updated by our quarterly reports on Form 10-Q, including the 10-Q we expect to file by Monday, November 16th. We undertake no obligation to update any forward-looking statements, except as required by law. During this call, we will also refer to certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net loss, and adjusted net loss per share. Reconciliations of these measures to the most directly comparable GAAP measures are included in our earnings press release, which is available on the investor relations section of our website. Also note that our share and per-share amounts reflect the 1-for-20 reverse stock split effected on September 8th, 2026. With that, I'll turn the call over to Phil. Phil?
Phillip Chan CEO Great. Thank you very much, Pete. Well, thanks, Pete, and good afternoon, everyone. I appreciate you joining us. This was an important quarter for Cytosorbents, not just because of the financial results, but because of what they tell us about the business that we're building.
Frequently Asked Questions About CTSO
Did CTSO beat earnings estimates last quarter?
Yes. Cytosorbents Crp reported EPS of -$0.58 for the quarter ended Sep 30, 2026, above the -$0.90 estimate, a 35.56% surprise.
What EPS do analysts expect from CTSO next quarter?
The consensus EPS estimate for Cytosorbents Crp for the quarter ending Dec 31, 2026 is -$0.71 from 5 analysts, with estimates from -$0.78 to -$0.63.
How often does CTSO beat earnings estimates?
Cytosorbents Crp beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -28.90%.
CTSO pages: Overview, Earnings, Forecast, Financials, Competitors